论文部分内容阅读
目的观察格列吡嗪控释片和格列美脲对T2DM的疗效。方法对86例新诊断T2DM患者随机分组为格列吡嗪控释片观察组45例和格列美脲对照组41例,观察临床降糖疗效和空腹及餐后2h血糖、胰岛素、C-肽的变化。观察组给予格列吡嗪控释片5mg,每日1次,餐前半小时口服,根据血糖变化情况,每1周～2周增加5mg,直到FPG<6.1～7.8mmol/L和2hPG7.8～10.0mmol/L,或每日最大推荐剂量20mg。对照组给予格列美脲片1mg,每日1次,餐前半小时或餐时口服,根据血糖变化情况,每1周～2周增加1mg,直到FPG<6.1～7.8mmol/L和2hPG7.8～10.0mmol/L,或每日最大推荐剂量6mg。2组疗程均为8周。结果格列吡嗪控释片有效地降低空腹血糖,总有效率为80%,与格列美脲对照组80.5%相似;降低餐后2h血糖总有效率86.7%,与对照组85.4%也相似;2组间差异无显著性(P>0.05)。治疗后4周、8周,2组各与治疗前相比,空腹胰岛素、C-肽差异无显著性(P>0.05),餐后胰岛素、C-肽差异有显著性(P<0.05);2组相比,差异无显著性(P>0.05)。结论格列吡嗪控释片和格列美脲可成为临床上治疗T2DM广泛应用的降糖药物。
Objective To observe the effects of glipizide controlled-release tablets and glimepiride on T2DM. Methods A total of 86 newly diagnosed T2DM patients were randomly divided into glipizide controlled-release group (n = 45) and glimepiride control group (n = 41). The clinical effects of hypoglycemic agents and fasting and postprandial blood glucose, insulin and C- The change. The observation group was given glipizide controlled-release tablets 5mg once a day orally for half an hour before meals, according to the changes in blood glucose every 5 weeks until 2 weeks FPG <6.1 ~ 7.8mmol / L and 2hPG7.8 ~ 10.0mmol / L, or daily maximum recommended dose of 20mg. The control group was given glimepiride 1mg, once a day, half an hour before meals or during meals orally, according to changes in blood glucose every 1 week ~ 2 weeks to increase 1mg, until FPG <6.1 ~ 7.8mmol / L and 2hPG7.8 ~ 10.0mmol / L, or daily maximum recommended dose of 6mg. The two groups were treated for 8 weeks. The results glipizide controlled release tablets effectively reduce fasting blood glucose, the total effective rate was 80%, and glimepiride control 80.5% similar; reduce 2h postprandial blood glucose total efficiency 86.7%, 85.4% with the control group is also similar There was no significant difference between the two groups (P> 0.05). The levels of fasting insulin and C-peptide had no significant difference (P> 0.05) at 4 weeks, 8 weeks and 2 weeks after treatment. There was significant difference between postprandial insulin and C-peptide (P <0.05) There was no significant difference between the two groups (P> 0.05). Conclusion Glipizide controlled-release tablets and glimepiride can be widely used in the treatment of T2DM hypoglycemic drugs.